BeOne Medicines Ltd.
ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$361.27−9.06 (-2.45%)
Close on Nov 2, 2026Market cap $41.08BP/E 64.6Yield –
BeOne Medicines Development Milestone Payments Expensed to R&D by Quarter
Development Milestone Payments Expensed to R&D ($M) ($M)
BeOne Medicines Development Milestone Payments Expensed to R&D: $3.30M in Q2 2026.
Latest, Q2 2026
3.30
Period ended Jun 30, 2026
Change on a year earlier
–
0 in Q2 2025
History
4 quarters
Since Q1 2023
Sources
2
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-05) ↗
Reported in Form 10-Q / 10-K Collaborative Arrangements Note (XBRL).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Development Milestone Payments Expensed to R&D ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 3.30 | – | Form 10-Q (filed 2026-08-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 0 | – | Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 35 | – | Form 10-Q (filed 2024-05-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 0 | – | Form 10-Q (filed 2024-05-08) ↗ |
Cite this data
StockData. (2026). BeOne Medicines Development Milestone Payments Expensed to R&D ($M), quarterly Q1 2023–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/rd-milestone
See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.